Evicenter
Darzalex (daratumumab) in Multiple myeloma
Manufacturer
Janssen Biotech, Inc.
Questions
61
Last updated

All questions

Clinical trials: Darzalex (daratumumab) in multiple myeloma

12 questions · 9 sources

Study results

How much does Darzalex (DRd) delay myeloma progression in patients ineligible for transplant (MAIA)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

Note: The 60-month progression-free rates and the hazard ratio of 0.55 are from the 64-month PFS tab of the MAIA efficacy page; the Prescribing Information reports the 64-month medians.

Do patients live longer on Darzalex with lenalidomide and dexamethasone (MAIA)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

Note: The 60-month and 89-month survival percentages are from the MAIA efficacy page (the 89-month figure from its 89-month OS tab); the Prescribing Information reports the 89-month medians.

What response and MRD-negativity rates did Darzalex (DRd) achieve in MAIA?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

Note: Table 23 columns are DRd (N=368) and Rd (N=369), in that order. The MAIA efficacy page reports the response and MRD results at a median follow-up of 28 months.

What MRD-negativity and complete response rates did Darzalex Faspro with VRd achieve (CEPHEUS)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

“a Based on intent-to-treat population unless otherwise noted. b The hierarchical testing order in the CEPHEUS study was overall MRD negativity rate followed by CR or better rate, PFS, and sustained MRD negativity rate. c Interim analysis: Median follow-up of 39 months (cut-off date 08 September 2022). d Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), and age/transplant eligibility (<70 years ineligible, or <70 years and refusal to transplant, or ≥70 years) as randomized. A hazard ratio <1 indicates an advantage for D-VRd. e p-value is based on the log-rank test stratified with ISS staging (I, II, III), and age/transplant eligibility (<70 years ineligible, or <70 years and refusal to transplant, or ≥70 years) as randomized. f Primary analysis: Median follow-up of 22 months (cut-off date 08 April 2021). g Patients achieved both MRD negativity (threshold of 10-5) and CR or better. All MRD testing was performed with a next-generation sequencing assay (clonoSEQ). h p-value from Cochran Mantel-Haenszel Chi-Squared test. i Patients achieving MRD negativity (threshold of 10-5) among only patients achieving a response of CR or better. j Exact 95% confidence interval. k Sustained MRD negativity is defined as confirmed MRD negative status at two examinations at least 1 year apart without MRD positive status in between. l p-value from Fisher’s exact test. m Final analysis: Median follow-up of 59 months (cut-off date 07 May 2024).” (opens the source at this quote in a new tab)

Note: Table 29 columns are DARZALEX FASPRO-VRd (N=197) and VRd (N=198), in that order. Footnotes f, c, and m date each row to the primary (22-month), interim (39-month), or final (59-month) analysis.

Does Darzalex Faspro with VRd delay myeloma progression in transplant-ineligible patients (CEPHEUS)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

“a Based on intent-to-treat population unless otherwise noted. b The hierarchical testing order in the CEPHEUS study was overall MRD negativity rate followed by CR or better rate, PFS, and sustained MRD negativity rate. c Interim analysis: Median follow-up of 39 months (cut-off date 08 September 2022). d Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), and age/transplant eligibility (<70 years ineligible, or <70 years and refusal to transplant, or ≥70 years) as randomized. A hazard ratio <1 indicates an advantage for D-VRd. e p-value is based on the log-rank test stratified with ISS staging (I, II, III), and age/transplant eligibility (<70 years ineligible, or <70 years and refusal to transplant, or ≥70 years) as randomized. f Primary analysis: Median follow-up of 22 months (cut-off date 08 April 2021). g Patients achieved both MRD negativity (threshold of 10-5) and CR or better. All MRD testing was performed with a next-generation sequencing assay (clonoSEQ). h p-value from Cochran Mantel-Haenszel Chi-Squared test. i Patients achieving MRD negativity (threshold of 10-5) among only patients achieving a response of CR or better. j Exact 95% confidence interval. k Sustained MRD negativity is defined as confirmed MRD negative status at two examinations at least 1 year apart without MRD positive status in between. l p-value from Fisher’s exact test. m Final analysis: Median follow-up of 59 months (cut-off date 07 May 2024).” (opens the source at this quote in a new tab)

Note: Table 29 columns are DARZALEX FASPRO-VRd (N=197) and VRd (N=198), in that order. The CEPHEUS efficacy page also shows a 59-month final analysis as a graphic.

Does Darzalex Faspro with VRd delay myeloma progression in transplant-eligible patients (PERSEUS)?

Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

Note: The median follow-up of 47.5 months is from the PERSEUS efficacy page of the Darzalex HCP site.

What response and MRD-negativity rates did Darzalex Faspro with VRd achieve (PERSEUS)?

Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

Note: Table 28 columns are DARZALEX FASPRO-VRd (n=355) and VRd (n=354), in that order; results are through the end of post-transplant consolidation.

How much does Darzalex Faspro lower the risk of progression in high-risk smoldering myeloma (AQUILA)?

Applies to High-risk smoldering multiple myeloma: DARZALEX FASPRO monotherapy vs active monitoring (AQUILA)

Note: The hazard ratio is from the AQUILA summary that the Darzalex HCP site links. Table 35 columns are DARZALEX FASPRO (n=194) and active monitoring (n=196), in that order.

Subgroup results

Does Darzalex Faspro with VRd lower progression risk in high-risk cytogenetics (PERSEUS post hoc)?

Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DVRd vs VRd, post hoc cytogenetic subgroup analysis of PERSEUS

Note: This is a post hoc analysis; results include the investigational DARZALEX FASPRO + lenalidomide maintenance phase.

Does Darzalex (DRd) work in patients 80 years and older (MAIA post hoc)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DRd vs Rd, post hoc subgroup analyses of MAIA

Does Darzalex (DRd) work in frail patients (MAIA post hoc)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DRd vs Rd, post hoc subgroup analyses of MAIA

Does Darzalex (DRd) work in patients with high-risk cytogenetics (MAIA post hoc)?

Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DRd vs Rd, post hoc subgroup analyses of MAIA